Summary
An immunohistochemical determination of the growth fraction (GF) with the Ki-67 monoclonal antibody has been performed in a prospective series of 140 patients with primary operable breast carcinoma. GF ranged from 0% to 43% Ki-67 stained cells with a median value of 8%. High GF (> 8%) was significantly associated with axillary node involvement (p = 0.006), aneuploidy (p = 0.008), histologic grade (p = 0.03), and S-phase fraction > 5% determined by flow cytometry (p = 0.01). After a median follow-up of 6 years, the univariate analysis did not show significant correlation between high GF and worse relapse-free survival (p = 0.10) or shorter overall survival. However, a multivariate analysis on relapse-free survival, performed in 127 comparable patients, showed that GF was an independent predictive factor (p = 0.03) together with nodal status (p = 0.00001), age under 45 years (p = 0.0008), and chemotherapy (0.006). In node negative patients, GF was still an independent prognostic indicator (p = 0.002) together with age under 45 years (p = 0.0003). Tumor proliferative activity evaluated by the monoclonal antibody Ki-67 appears to be an effective indicator of prognosis in breast cancer and could be of assistance in the decision making of adjuvant therapy in node negative patients.
Article PDF
Avoid common mistakes on your manuscript.
References
Meyer JS, Friedman E, McRate MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labelling. Cancer 51: 1879–1886, 1983
Tubiana M, Pejovic MJ, Chavaudra N, Contesso G, Malaise E: The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 33: 441–445, 1984
Clark GM, Dressler LG, Marilyn AO, Pounds G, Oldaker T, McGuire W: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989
Meyer JS, Coplin MD: Thymidine labeling index, flow cytometric S-phase measurement and DNA index in human tumors: comparisons and correlations. Am J Clin Pathol 89: 586–595, 1988
Viehl P, Chevillard S, Mosseri V, Donatini B, Magdelenat H: Ki-67 index and S-phase fraction in human breast carcinomas. Am J Clin Pathol 94: 681–686, 1990
Remvikos Y: Prognostic value of the S-phase fraction of breast cancer. Br J Cancer 68: 433–434, 1993
Gerdes J, Li L, Schlüter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867–873, 1991
Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123: 513–522, 1993
Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa APM, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU anti-Ki67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 29A: 1509–1513, 1993
Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 81: 3926–3931, 1993
Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20, 1983
Osborne CK: Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10: 679–682, 1992
Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045–1053, 1990
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–366, 1957
Magdelénat H, Lainé-Bidron C, Merle S, Zajdela A: Estrogen and progestin receptor assay in fine needle aspirates of breast cancer: methodological aspect. Eur J Cancer Clin Oncol 23: 425–431, 1987
Baisch H, Gohde W, Linden WA: Mathematical analysis of pulse-cytophotometric data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 12: 31–39, 1975
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170, 1966
Cox DR: Regression models and life tables (with discussion). J Stat Soc B 34: 187–220, 1972
Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey RW, Nicholson KI: Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943–947, 1989
Gasparini G, Pozza F, Meli S, Reitano M, Santini G, Bevilacqua P: Breast cancer cell kinetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anti-Cancer Res 11: 2015–2022, 1991
Weickel W, Beck T, Mitze M, Knapstein PG: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154, 1991
Wintzer HO, Zipfel I, Schulte-Möntig J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421–428, 1991
Gasparini G, Pozza F, Bevilacqua P, Meli S, Boracchi P, Reitano M, Santini G, Marubini E, Sainsbury JRC: Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: histologic, clinical and prognostic correlations. The Breast 1: 92–99, 1992
Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllönen L, von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68: 579–583, 1993
Rudas M, Gnant MFX, Mittlböck M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 32: 165–176, 1994
de la Rochefordière A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelénat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039–1043, 1993
Sahin AA, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonnez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG: Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Cancer 68: 549–557, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pierga, J.Y., Leroyer, A., Viehl, P. et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Tr 37, 57–64 (1996). https://doi.org/10.1007/BF01806632
Issue Date:
DOI: https://doi.org/10.1007/BF01806632